Shares of Okpo Health jump on plans to test vitamin D drug in COVID-19 patients

/ / News

Shares of Opko Health were up 3.8% in premarket trading on Tuesday after the company said it is testing Rayaldee as a treatment for mild-to-moderate COVID-19 in a Phase 2, randomized, double-blind, placebo-controlled study. Rayaldee is a vitamin D-based drug that has been approved by the Food and Drug Administration as a treatment for certain forms of kidney disease. The trial’s 160 participants will primarily include people with stage 3 or 4 chronic kidney disease. Research published Sept. 3 in the JAMA Network identified that “likely deficient vitamin D status was associated with increased COVID-19 risk.” Opko’s stock has soared 115.6% so far this year, while the S&P 500 is up 3.4%.
Market Pulse Stories are Rapid-fire, short news bursts on stocks and markets as they move. Visit MarketWatch.com for more information on this news.